on MAAT PHARMA (isin : FR0012634822)
MaaT Pharma announces a capital increase of 13 million euros and 2024 annual results
MaaT Pharma has raised €13 million from its long-standing shareholders, including Biocodex and Fonds PSIM, to support its future developments. This funding comes as the company announces its financial and operating results for 2024. Results from the Phase 3 trial for MaaT013 in acute graft-versus-host disease (aGvHD) showed high efficacy with a response rate of 62% at day 28. Revenue reached €3.2 million, marking a 44% increase compared to 2023. Cash available as of December 31, 2024, amounted to €20.2 million, enabling the company to finance its operations until October 2025.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MAAT PHARMA news